본문 바로가기

Neurobiology of ARID1B haploinsufficiency related to neurodevelopmental and psychiatric disorders

문서 유형
연구출판물 · 리뷰논문
등재
Nature IndexSCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
MOLECULAR PSYCHIATRY27(1) · pp.476 · 2022
피인용
Web of Science 47Scopus 49
FWCI (Scopus)
1.18
JCR IF
JCR 2021 13.437
ISSN
1359-4184

저자

  1. Moffat, Jeffrey J.제1저자Department of Neurology, University of California San Francisco, San Francisco, CA, USA
  2. Smith, Amanda L.Developmental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
  3. 정의만Department of Molecular Biology, College of Natural Sciences, Pusan National University, Busan, Republic of Korea
  4. Ka, MinhanResearch Center for Substance Abuse Pharmacology, Korea Institute of Toxicology, Daejeon, Republic of Korea
  5. Kim, Woo-Yang교신저자Department of Biological Sciences, Kent State University, Kent, OH, USA

초록

ARID1B haploinsufficiency is a frequent cause of intellectual disability (ID) and autism spectrum disorder (ASD), and also leads to emotional disturbances. In this review, we examine past and present clinical and preclinical research into the neurobiological function of ARID1B. The presentation of ARID1B-related disorders (ARID1B-RD) is highly heterogeneous, including varying degrees of ID, ASD, and physical features. Recent research includes the development of suitable clinical readiness assessments for the treatment of ARID1B-RD, as well as similar neurodevelopmental disorders. Recently developed mouse models of Arid1b haploinsufficiency successfully mirror many of the behavioral phenotypes of ASD and ID. These animal models have helped to solidify the molecular mechanisms by which ARID1B regulates brain development and function, including epigenetic regulation of the Pvalb gene and promotion of Wnt/beta-catenin signaling in neural progenitors in the ventral telencephalon. Finally, preclinical studies have identified the use of a positive allosteric modulator of the GABA(A) receptor as an effective treatment for some Arid1b haploinsufficiency-related behavioral phenotypes, and there is potential for the refinement of this therapy in order to translate it into clinical use.

키워드

CHROMATIN-REMODELING COMPLEXSOMATOSTATIN-EXPRESSING NEURONSAUTISM SPECTRUM DISORDERCOFFIN-SIRIS SYNDROMEINTELLECTUAL DISABILITYGABAERGIC INTERNEURONSSYNAPTIC CURRENTSUNITED-STATESMOUSE MODELPREVALENCE

식별자

Scopus EID
2-s2.0-85102367892
WoS UID
000626433200002